NewsBenzingaジョンソン・エンド・ジョンソン、主要な自己免疫疾患治療薬の有望な臨床試験データを発表 ジョンソン・エンド・ジョンソン、主要な自己免疫疾患治療薬の有望な臨床試験データを発表 Benzinga 2026.11.09 15:04 (GMT+0) Open on Benzinga Other news Canaccord Genuity Maintains Buy on Belite Bio, Raises Price Target to $314 Applied Optoelectronics Stock Sinks Amid AI Outlook Fears Canaccord Genuity Maintains Buy on Enovix, Lowers Price Target to $2.5 Canaccord Genuity Maintains Buy on Intuitive Machines, Lowers Price Target to $38 'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149
'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report